Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform

Risk Analysis

Volumn 27, Issue 6, 2007, Pages 1535-1551

  Liao, Kai H ^a,b   Tan, Yu Mei ^a   Conolly, Rory B ^a,c   Borghoff, Susan J ^a,d   Gargas, Michael L ^a,e   Andersen, Melvin E ^a   Clewell III, Harvey J ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b WYETH RESEARCH   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d INTEGRATED LABORATORY SYSTEMS   (United States)

^e Sapphire Group Inc   (United States)

Author keywords

Chloroform; Markov Chain Monte Carlo (MCMC) analysis; Physiologically based pharmacokinetic pharmacodynamic (PBPK PD) modeling; Risk assessment

Indexed keywords

BAYESIAN NETWORKS; CARCINOGENS; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; HIDDEN MARKOV MODELS; ONCOLOGY; PHARMACOKINETICS; RATS; RISK ASSESSMENT;

DOSE-RESPONSE ASSESSMENT; INHALATION EXPOSURES; INHALATION REFERENCE CONCENTRATIONS; KIDNEY DOSE METRICS; MARKOV CHAIN MONTE CARLO (MCMC) ANALYSIS; ORAL REFERENCE DOSES; RENAL LABELING INDEX DATA;

CHLORINE COMPOUNDS;

CHLOROFORM;

BAYESIAN ANALYSIS; CARCINOGEN; CHLOROFORM; DOSE-RESPONSE RELATIONSHIP; MARKOV CHAIN; METABOLISM; MONTE CARLO ANALYSIS; RISK ASSESSMENT; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAYES THEOREM; CANCER RISK; CARCINOGENICITY; CELL DAMAGE; CELL DEATH; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; EXPOSURE; FEMALE; KIDNEY METABOLISM; LABELING INDEX; LIVER METABOLISM; MALE; METABOLISM; MONTE CARLO METHOD; MOUSE; NONHUMAN; PARAMETER; PARTITION COEFFICIENT; PROBABILITY; REFERENCE VALUE; RISK ASSESSMENT; SEX RATIO;

ANIMALS; BAYES THEOREM; BIOLOGICAL TRANSPORT, ACTIVE; CARCINOGENS; CHLOROFORM; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; KIDNEY; LIVER; MALE; MARKOV CHAINS; MICE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; RISK ASSESSMENT;

MUS; RATTUS; RODENTIA;

EID: 37249010181     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2007.00987.x     Document Type: Article

References (46)

1. U.S. EPA 2005). Guidelines for Carcinogen Risk Assessment; EPA/630/P-03/001F; Risk Assessment Forum, Washington, DC: U.S. Environmental Protection Agency.
2. ILSI 1997). An Evaluation of EPA's Proposed Guidelines for Carcinogen Risk Assessment Using Chloroform and Dichloroacetate as Case Studies: Report of an Expert Panel. Washington, DC: International Life Sciences Institute.
3. U.S. EPA 2001). Toxicological Review for Chloroform: In Support of Summary Information on the Integrated Risk Information System (IRIS) EPA/635/R-01/001 Washington, DC: U.S. Environmental Protection Agency.
4. Clewell, H. J., & Andersen, M. E. (2004). Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: An example with trichloroethylene. Critical Reviews in Toxicology, 34, 385 445.
5. Clewell, H. J., Gentry, P. R., Gearhart, J. M., Allen, B. C., & Andersen, M. E. (2001). Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Science of the Total Environment, 274, 37 66.
6. Clewell, H. J., Gentry, P. R., Kester, J. E., & Andersen, M. E. (2005). Evaluation of physiologically based pharmacokinetic models in risk assessment: An example with perchloroethylene. Critical Reviews in Toxicology, 35, 413 433.
7. Andersen, M. E., Clewell, H. J., Gargas, M. L., Smith, F. A., & Reitz, R. H. (1987). Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicology and Applied Pharmacology, 87, 185 205.
8. Gentry, P. R., Covington, T. R., Andersen, M. E., & Clewell, H. J. (2002). Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regulatory Toxicology and Pharmacology, 36, 51 68.
9. Bois, F. Y. (1999). Analysis of PBPK models for risk characterization. Annals of the New York Academy of Sciences, 895, 317 337.
10. Gelman, A., Bois, F., & Jiang, J. M. (1996). Physiological pharmacokinetic analysis using population modeling and informative prior distributions. Journal of the American Statistical Association, 91, 1400 1412.
11. Corley, R. A., Mendrala, A. L., Smith, F. A., Staats, D. A., Gargas, M. L., Conolly, R. B., Andersen, M. E., & Reitz, R. H. (1990). Development of a physiologically based pharmacokinetic model for chloroform. Toxicology and Applied Pharmacology, 103, 512 527.
12. Health Canada, Canadian Environmental Protection Act 1999). Priority Substances List Assessment Report: Chloroform. In Health Canada, Ottawa, Ontario.
13. Tan, Y. M., Butterworth, B. E., Gargas, M. L., & Conolly, R. B. (2003). Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. Toxicology Science, 75, 192 200.
14. Templin, M. V., Constan, A. A., Wolf, D. C., Wong, B. A., & Butterworth, B. E. (1998). Patterns of chloroform-induced regenerative cell proliferation in BDF1 mice correlate with organ specificity and dose-response of tumor formation. Carcinogenesis, 19, 187 193.
15. Templin, M. V., Larson, J. L., Butterworth, B. E., Jamison, K. C., Leininger, J. R., Mery, S., Morgan, K. T., Wong, B. A., & Wolf, D. C. (1996). A 90-day chloroform inhalation study in F-344 rats: Profile of toxicity and relevance to cancer studies. Fundamental Applied Toxicology, 32, 109 125.
16. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health, 13, 407 484.
17. Lipscomb, J. C., Barton, H. A., Tornero-Velez, R., Evans, M. V., Alcasey, S., Snawder, J. E., & Laskey, J. (2004). The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A, 67, 537 553.
18. Bernillon, P., & Bois, F. Y. (2000). Statistical issues in toxicokinetic modeling: A Bayesian perspective. Environmental Health Perspectives, 108, 883 893.
19. Bois, F. Y., & Maszle, D. R. (2005). MCSim: A Monte Carlo Simulation Program. Available at http://toxi.ineris.fr/activites/toxicologie_quantitative/ mcsim/mcsim.php.
20. Metropolis, N., Rosenbluth, A. W., Rosenbluth, M. N., Teller, A. H., & Teller, E. (1953). Equation of state calculations by fast computing machines. Journal of Chemical Physics, 21, 1087 1092.
21. Hastings, W. K. (1970). Monte-Carlo sampling methods using Markov chains and their applications. Biometrika, 57, 97 109.
22. Gearhart, J. M., Seckel, C., & Vinegar, A. (1993). In vivo metabolism of chloroform in B6C3F1 mice determined by the method of gas uptake: The effects of body temperature on tissue partition coefficients and metabolism. Toxicology and Applied Pharmacology, 119, 258 266.
23. Yamamoto, S., Kasai, T., Matsumoto, M., Nishizawa, T., Arito, H., Nagano, K., & Matsushima, T. (2002). Carcinogenicity and chronic toxicity in rats and mice exposed to chloroform by inhalation. Journal of Occupational Health, 44, 283 293.
24. Henderson, C. J., Scott, A. R., Yang, C. S., & Wolf, C. R. (1990). Testosterone-mediated regulation of mouse renal cytochrome P-450 isoenzymes. Biochemical Journal, 266, 675 681.
25. Henderson, C. J., & Wolf, C. R. (1991). Evidence that the androgen receptor mediates sexual differentiation of mouse renal cytochrome P450 expression. Biochemical Journal, 278, 499 503.
26. Guengerich, F. P., Kim, D. H., & Iwasaki, M. (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low-molecular-weight cancer suspects. Chemical Research in Toxicology, 4, 168 179.
27. Arms, A. D., & Travis, C. C. (1988). Reference Physiological Parameters in Pharmacokinetic Modeling. EPA/600/6-88/004. Washington, DC: U.S. Environmental Protection Agency.
28. OSHA 1997). Occupational Exposure to Methylene Chloride - 68:1494-1619. In Occupational Safety and Health Administration.
29. Bois, F. Y. (2000). Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environmental Health Perspectives, 108, 307 316.
30. Carlin, B. P., & Louis, T. A. (2000). Bayes and Empirical Bayes Methods for Data Analysis, 2 ed. Boca Raton: Chapman & Hall/CRC.
31. Larson, J. L., Wolf, D. C., & Butterworth, B. E. (1993). Acute hepatotoxic and nephrotoxic effects of chloroform in male F344 rats and female B6C3F1 mice. Fundamental and Applied Toxicology, 20, 302 315.
32. Sarangapani, R., Gentry, P. R., Covington, T. R., Teeguarden, J. G., & Clewell, H. J., 3rd. 2003). Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal Toxicol, 15, 987 1016.
33. Ogiu, N., Nakamura, Y., Ijiri, I., Hiraiwa, K., & Ogiu, T. (1997). A statistical analysis of the internal organ weights of normal Japanese people. Health Physics, 72, 368 383.
34. Rubin, M. I., Bruck, E., & Rapoport, M. (1949). Maturation of renal function in childhood - Clearance studies. Journal of Clinical Investigation, 28, 1144 1162.
35. Gelman, A. (1996). Inference and monitoring convergence. In W. R. Gilks, S. Richardson, & D. J. Spiegelhalter (Eds. Markov Chain Monte Carlo in Practice pp. 131 143). Boca Raton: Chapman & Hall/CRC.
36. Brooks, S. P., & Gelman, A. (1998). General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics, 7, 434 455.
37. Smith, B. J. (2005). Bayesian Output Analysis Program (BOA) Version 1.1 User's Manual. Available at http://www.public-health.uiowa.edu/boa/.
38. U.S. EPA 2001). IRIS listing for chloroform. Available at: http://www.epa.gov/iris/subst/0025.htm.
39. U.S. EPA (2006). Use of Physiologically Based Pharmacokinetic Models to Quantify the Impact of Human Age and Interindividual Differences in Physiology and Biochemistry Pertinent to Risk. EPA/600/R-06/014A Cincinnati, OH: National Center for Environmental Assessment, U.S. Environmental Protection Agency.
40. David, R. M., Clewell, H. J., Gentry, P. R., Covington, T. R., Morgott, D. A., & Marino, D. J. (2006). Revised assessment of cancer risk to dichloromethane - II. Application of probabilistic methods to cancer risk determinations. Regulatory Toxicology and Pharmacology, 45, 55 65.
41. Jonsson, F., Bois, F. Y., & Johanson, G. (2001). Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Archives of Toxicology, 75, 189 199.
42. Jonsson, F., & Johanson, G. (2001). A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicology and Applied Pharmacology, 174, 99 112.
43. Jonsson, F., & Johanson, G. (2001). Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology, 157, 177 93.
44. Jonsson, F., & Johanson, G. (2002). Physiologically based modeling of the inhalation kinetics of styrene in humans using a Bayesian population approach. Toxicology and Applied Pharmacology, 179, 35 49.
45. Marino, D. J., Clewell, H. J., Gentry, P. R., Covington, T. R., Hack, C. E., David, R. M., & Morgott, D. A. (2006). Revised assessment of cancer risk to dichloromethane: Part I - Bayesian PBPK and dose-response modeling in mice. Regulatory Toxicology and Pharmacology, 45, 44 54.
46. Templin, M. V., Larson, J. L., Butterworth, B. E., Jamison, K. C., Leininger, J. R., Mery, S., Morgan, K. T., Wong, B. A., & Wolf, D. C. (1996). A 90-day chloroform inhalation study in F-344 rats: Profile of toxicity and relevance to cancer studies. Fundamental and Applied Toxicology, 32, 109 125.